{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:54:03Z","timestamp":1790502843498,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA192393"],"award-info":[{"award-number":["CA192393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA116167"],"award-info":[{"award-number":["CA116167"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA176785"],"award-info":[{"award-number":["CA176785"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10549-016-4085-4","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T04:43:21Z","timestamp":1482554601000},"page":"575-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results"],"prefix":"10.1007","volume":"161","author":[{"given":"Mary","family":"Pritzlaff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Summerour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Reineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Dolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Goldgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermela","family":"Shimelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"LaDuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,22]]},"reference":[{"key":"4085_CR1","unstructured":"The NCCN Clinical Practice Guidelines in Oncology\u2122 Genetic\/Familial High-Risk Assessment: Breast and Ovarian V2.2016. National Comprehensive Cancer Network, Inc. 2016. \n                    http:\/\/www.nccn.org\/\n                    \n                  . Accessed 22 Sept 2016"},{"issue":"5","key":"4085_CR2","first-page":"1079","volume":"60","author":"S Thorlacius","year":"1997","unstructured":"Thorlacius S, Sigurdsson S, Bjarnadottir H et al (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60(5):1079\u20131084","journal-title":"Am J Hum Genet"},{"issue":"1","key":"4085_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ng0596-123","volume":"13","author":"FJ Couch","year":"1996","unstructured":"Couch FJ, Faird LM, SeSHano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123\u2013125","journal-title":"Nat Genet"},{"issue":"6","key":"4085_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480\u20131490","journal-title":"J Clin Oncol"},{"issue":"9","key":"4085_CR5","doi-asserted-by":"publisher","first-page":"e43994","DOI":"10.1371\/journal.pone.0043994","volume":"7","author":"A Kwong","year":"2012","unstructured":"Kwong A, Ng EK, Wong CL et al (2012) Identification of BRCA1\/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS ONE 7(9):e43994","journal-title":"PLoS ONE"},{"issue":"3","key":"4085_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10549-012-2001-0","volume":"133","author":"BH Son","year":"2012","unstructured":"Son BH, Ahn SH, Kim SW et al (2012) Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study. Breast Cancer Res Treat 133(3):1143\u20131152","journal-title":"Breast Cancer Res Treat"},{"key":"4085_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12885-016-2414-y","volume":"16","author":"P Gargiulo","year":"2016","unstructured":"Gargiulo P, Pensabene M, Milano M et al (2016) Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer 16:375","journal-title":"BMC Cancer"},{"issue":"1","key":"4085_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25 gene panel. Cancer 121(1):25\u201333","journal-title":"Cancer"},{"issue":"8","key":"4085_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18(8):823\u2013832","journal-title":"Genet Med"},{"key":"4085_CR10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","unstructured":"Breast Cancer Linkage Consortium (1999) Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310\u20131316","journal-title":"J Natl Cancer Inst"},{"key":"4085_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700\u2013710","journal-title":"Am J Hum Genet"},{"key":"4085_CR12","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF (2002) The breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358\u20131365","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4085_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55\u201359","journal-title":"Nat Genet"},{"issue":"2","key":"4085_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-008-0162-7","volume":"116","author":"M Wasielewski","year":"2009","unstructured":"Wasielewski M, den Bakker MA, van den Ouweland A et al (2009) CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 116(2):397\u2013400","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4085_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ijc.11384","volume":"108","author":"K Syrjakoski","year":"2004","unstructured":"Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108(3):475\u2013476","journal-title":"Int J Cancer"},{"issue":"3","key":"4085_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ijc.11603","volume":"108","author":"T Ohayon","year":"2004","unstructured":"Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108(3):479\u2013480","journal-title":"Int J Cancer"},{"issue":"3","key":"4085_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ijc.11385","volume":"108","author":"S Neuhausen","year":"2004","unstructured":"Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1\/2 male breast cancers. Int J Cancer 108(3):477\u2013478","journal-title":"Int J Cancer"},{"issue":"3","key":"4085_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.20073","volume":"110","author":"MR Dufault","year":"2004","unstructured":"Dufault MR, Betz B, Wappenschmidt B et al (2004) Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110(3):320\u2013325","journal-title":"Int J Cancer"},{"key":"4085_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2350-4-1","volume":"4","author":"K Offit","year":"2003","unstructured":"Offit K, Pierce H, Kirchhoff T et al (2003) Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4:1","journal-title":"BMC Med Genet"},{"issue":"1","key":"4085_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-007-9689-2","volume":"110","author":"M Falchetti","year":"2008","unstructured":"Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1\/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110(1):161\u2013167","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4085_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-007-9878-z","volume":"112","author":"DH Choi","year":"2008","unstructured":"Choi DH, Cho DY, Lee MH et al (2008) The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat 112(3):569\u2013573","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"4085_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10689-007-9153-9","volume":"7","author":"DG Evans","year":"2008","unstructured":"Evans DG, Bulman M, Young K et al (2008) BRCA1\/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7(2):113\u2013117","journal-title":"Fam Cancer"},{"issue":"3","key":"4085_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10549-010-1195-2","volume":"126","author":"YC Ding","year":"2011","unstructured":"Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL (2011) Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 126(3):771\u2013778","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4085_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jmg.38.3.159","volume":"38","author":"JD Fackenthal","year":"2001","unstructured":"Fackenthal JD, Marsh DJ, Richardson AL et al (2001) Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38(3):159\u2013164","journal-title":"J Med Genet"},{"issue":"1\u20133","key":"4085_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2013.03.037","volume":"717","author":"B Sousa","year":"2013","unstructured":"Sousa B, Moser E, Cardoso F (2013) An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 717(1\u20133):71\u201383","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"4085_CR26","doi-asserted-by":"publisher","first-page":"e52271","DOI":"10.1371\/journal.pone.0052271","volume":"7","author":"YN Song","year":"2012","unstructured":"Song YN, Geng JS, Liu T et al (2012) Long CAG repeat sequence and protein expression of androgen receptor considered as prognostic indicators in male breast carcinoma. PLoS ONE 7(12):e52271","journal-title":"PLoS ONE"},{"issue":"11","key":"4085_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D et al (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29(11):1282\u20131291","journal-title":"Hum Mutat"},{"issue":"5","key":"4085_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424","journal-title":"Genet Med"},{"key":"4085_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2469523","volume":"2016","author":"T Pesaran","year":"2016","unstructured":"Pesaran T, Karam R, Huether R et al (2016) Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes. Int J Breast Cancer 2016:1\u201310","journal-title":"Int J Breast Cancer"},{"key":"4085_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285\u2013291","journal-title":"Nature"},{"key":"4085_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5495","author":"BM Norquist","year":"2015","unstructured":"Norquist BM, Harrell MI, Brady MF et al (2015) Inherited mutations in women with ovarian carcinoma. JAMA Oncol. doi:\n                    10.1001\/jamaoncol.2015.5495","journal-title":"JAMA Oncol"},{"key":"4085_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443\u2013453","journal-title":"N Engl J Med"},{"key":"4085_CR33","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (\n                    www.seer.cancer.gov\n                    \n                  ) SEER Stat Fact Sheets: Prostate Cancer (SEER 18 2009-2013). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. \n                    https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\n                    \n                  . Accessed 9 Sept 2016"},{"issue":"6","key":"4085_CR34","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","volume":"71","author":"S Casadei","year":"2011","unstructured":"Casadei S, Norquist BM, Walsh T et al (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 71(6):2222\u20132229","journal-title":"Cancer Res"},{"issue":"6","key":"4085_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497\u2013506","journal-title":"N Engl J Med"},{"issue":"2","key":"4085_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165\u2013167","journal-title":"Nat Genet"},{"issue":"1","key":"4085_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-011-1842-2","volume":"132","author":"A Blanco","year":"2012","unstructured":"Blanco A, de la Hoya M, Balmana J et al (2012) Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat 132(1):307\u2013315","journal-title":"Breast Cancer Res Treat"},{"key":"4085_CR38","unstructured":"LaDuca H, McFarland R, Gutierrez S et al (2016) Taming concerns regarding the accuracy of laboratory clinical data: a detailed comparative analysis. Abstract, American Society of Human Genetics: ACMG Abstract 741F"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-4085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-4085-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-4085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:54:06Z","timestamp":1589720046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-4085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["4085"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-4085-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]},"assertion":[{"value":"8 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Mary Pritzlaff, Pia Summerour, Shuwei Li, Patrick Reineke, Jill S. Dolinsky, Rachel McFarland, and Holly LaDuca are employees of Ambry Genetics. Jill S. Dolinsky and Elizabeth Chao are stock holders of Ambry Genetics. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. The research presented here complies with the current laws of the United States of America.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}